Goldman Sachs’s TG Therapeutics TGTX Stock Holding History

Goldman Sachs’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.3M	Buy	+550,000	New	+$16.4M	﹤0.01%	2519

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs's TGTX Position: Q1 2026 in Review

Goldman Sachs increased its TG Therapeutics (TGTX) stake by 12% in Q1 2026, buying an estimated $7.05M and bringing the position to 2,287,688 shares worth $76M. The position accounts for 0.01% of the portfolio, ranked #1238.

Goldman Sachs first reported a position in TGTX in Q2 2013 and has held it in 42 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Goldman Sachs held 2,287,688 shares of TG Therapeutics worth $76M as of Q1 2026.
Goldman Sachs bought 236,556 TG Therapeutics shares in Q1 2026, an estimated $7.05M.
TG Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1238 holding.
Goldman Sachs first reported a position in TG Therapeutics in Q2 2013 and has held it in 42 quarters since.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.